Dendritic cells in cancer immunotherapy.
DC initiate and regulate T-cell immunity and are thus the key to optimization of all types of vaccines. Insights into DC biology offer many opportunities to enhance immunogenicity. In this Viewpoint, I discuss some recent developments and findings that are of immediate relevance for the clinical development of cancer vaccines. In addition, I emphasize my personal view that we should explore the potential of adoptively transferred DC (i.e. DC vaccination) as cancer vaccines by performing two-armed trials that address critical variables and by delivering antigens via mRNA-transfected DC.
Schuler
Gerold
G
Department of Dermatology, University Hospital Erlangen, Erlangen, Germany. gerold.schuler@uk-erlangen.de
D000818:Animals; D017951:Antigen Presentation / Q000235:genetics; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D019496:Cancer Vaccines; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism* / Q000473:pathology / Q000637:transplantation; D005818:Genetic Engineering; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000639:trends; D008213:Lymphocyte Activation / Q000235:genetics; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines